Akari Therapeutics Unveils Promising Preclinical Data for Prostate Cancer Targeting

Akari Therapeutics shares are trading higher after the company announced promising preclinical data demonstrating the potential of its novel ADC payload, PH1, which shows effectiveness in targeting AR-V7 driven tumors in prostate cancer.